Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a pioneering developer of minimally invasive devices for treating venous thromboembolism and related vascular conditions. This page provides investors and healthcare professionals with essential updates on corporate developments, financial performance, and clinical advancements.
Access real-time announcements including quarterly earnings reports, FDA clearances, clinical trial data, and strategic partnerships. Our curated news feed ensures you stay informed about NARI's innovative thrombectomy technologies and market positioning within the interventional medical device sector.
Key updates include product launch details, regulatory milestones, peer-reviewed study publications, and executive leadership changes. All content is sourced directly from verified company communications and SEC filings to ensure accuracy.
Bookmark this page for streamlined access to Inari Medical's latest developments. For comprehensive analysis of how these updates may impact long-term growth strategies, consult your financial advisor.
Inari Medical, Inc. (NARI) reported first-quarter 2021 revenue of $57.4 million, a significant 113% increase compared to the same period last year and an 18% sequential growth. The company treated a record number of patients and enrolled the first patient in the FLAME study, a pivotal clinical trial for high-risk pulmonary embolism patients. Operating expenses rose to $45.1 million, largely due to increased personnel costs. Net income was $7.5 million, with an EPS of $0.15. The company forecasts 2021 revenue between $240 million to $250 million.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in the 2021 Bank of America Healthcare Conference on May 13, 2021, at 8:45 a.m. ET. This commercial-stage medical device company focuses on innovative products for venous diseases. Inari has developed two FDA-cleared devices: the ClotTriever for deep vein thrombosis and the FlowTriever for pulmonary embolism. Both systems are designed to effectively remove large clots without the need for thrombolytic drugs, enhancing patient outcomes in treating venous thromboembolism.
Inari Medical (NASDAQ: NARI) announced its financial results for Q1 2021 will be released on May 11, 2021. A conference call and webcast will occur the same day at 1:30 PM PT / 4:30 PM ET to discuss the results and recent highlights. Inari is a commercial-stage medical device company focused on innovative treatments for venous diseases. Its key products include the ClotTriever and FlowTriever systems, both FDA cleared and CE Mark approved for treating deep vein thrombosis and pulmonary embolism.
Inari Medical, Inc. (NASDAQ: NARI) has announced a global partnership with Aidoc, an AI solutions provider, to enhance the detection and treatment of pulmonary embolism (PE). The collaboration aims to integrate AI into clinical pathways, improving patient outcomes by rapidly triaging scans for suspected PE. With recent studies indicating that many high-risk PE patients do not receive timely care, this partnership seeks to leverage technology to optimize treatment pathways. Key executives from both companies highlighted the significance of AI in transforming patient care standards.
Inari Medical, Inc. (NASDAQ: NARI) has enrolled its first high-risk pulmonary embolism (PE) patient in the FLAME study, which aims to evaluate treatment outcomes in up to 250 high-risk PE patients. This multicenter observational study, the largest of its kind, seeks to change treatment guidelines by examining patients treated with FlowTriever and those managed conservatively. Additionally, Inari is expanding the FLASH study to 1,000 patients to gather more data and is set to monitor patients using the Apple Watch, emphasizing their commitment to tackling pulmonary embolism with innovative studies.
Inari Medical (NASDAQ: NARI) reported strong Q4 2020 results, with revenue of $48.6 million, a 26% sequential increase, and 144% year-over-year growth. The company treated a record 4,600 patients, reflecting a 24% sequential rise. Their gross profit reached $44.9 million, with a gross margin of 92.4%. For 2020, total revenue was $139.7 million, up from $51.1 million in 2019, and net income was $13.8 million. Despite COVID-19 challenges, Inari expects Q1 2021 revenue between $54-$56 million and full-year 2021 revenue of $225-$235 million.
Inari Medical, Inc. (NASDAQ: NARI) will announce its fourth quarter and full year 2020 financial results on March 9, 2021, after market close. Following the announcement, a conference call is scheduled at 1:30 p.m. PST / 4:30 p.m. EST to discuss the results and recent highlights. Inari specializes in developing medical devices for venous diseases, with notable products like the ClotTriever and FlowTriever systems, designed for thrombosis treatment. Both systems are FDA cleared and CE Mark approved.
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The BTIG Virtual MedTech Conference will take place on February 17, 2021, at 4:00 p.m. ET, while the SVB Leerink Partners Virtual Global Healthcare Conference is scheduled for February 24, 2021, at 1:00 p.m. ET. Both presentations will be available for live streaming on the company’s Investor Relations webpage. Inari specializes in medical devices for venous disease treatment, with products like the ClotTriever and FlowTriever systems designed for thrombectomy.
Inari Medical, Inc. (NASDAQ: NARI) announced positive interim results from the ClotTriever Outcomes Registry, focusing on 64 chronic DVT patients. The ClotTriever device removed a median of 90% of clots in a single session without thrombolytics, with no serious adverse events reported. The median procedure time was 34 minutes, and the median blood loss was 50cc. Inari's recent CE Mark approval allows for global commercialization, enhancing treatment options for venous disease patients. The company has treated over 20,000 VTE patients, emphasizing the ongoing need for improved therapies.
Inari Medical, Inc. (NASDAQ: NARI) reported preliminary unaudited revenue for Q4 2020, estimating between $47.9 million and $48.9 million, marking a 141% to 146% increase year-over-year and a 24% to 26% rise from Q3 2020. The company performed approximately 4,600 procedures in Q4, up 156% year-over-year and 24% from the prior quarter. The COVID-19 pandemic posed challenges, yet the CEO expressed confidence in strategic execution and upcoming earnings report.
Full financial results will be disclosed in the Annual Report on Form 10-K.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
